EHACART

Cecilia BrownMeeting News | February 21, 2023
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
Read More
Cecilia BrownTransplantation & Cellular Therapy | February 21, 2023
The study's investigators identified a four-gene model that segregated patients with different survival probabilities.
Cecilia BrownMeeting News | February 16, 2023
The estimated 24-month nonrelapse mortality was significantly lower in the CAR-T cohort than in the allogeneic HSCT cohort.
Advertisement
Leah SherwoodMyeloma | April 12, 2023
The research shows an emerging target for the development of novel CAR T-cell immunotherapies.
Cecilia BrownFollicular Lymphoma | April 12, 2023
The researchers reported “high rates of durable responses” in most patients who were in high-risk disease subgroups.
Cecilia BrownMyeloma | April 12, 2023
Idecabtagene vicleucel led to “deeper and more durable responses” than standard regimens in the KarMMa-3 trial.
Advertisement
Cecilia BrownTransplantation & Cellular Therapy | February 10, 2023
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Leah SherwoodAggressive B-Cell Lymphoma | April 12, 2023
The results showed pembrolizumab was well tolerated, with 23.5% of patients achieving a complete response.
Cecilia BrownAcute Lymphoblastic Leukemia | March 10, 2023
All patients had a complete response after the first infusion, while 67% had a complete response after the second infusion.
Advertisement
Advertisement
Editorial Board